KingMed Diagnostics and WuXi AppTech have contributed to a $28m round that will fund the precision medicine developer's cancer DNA research.
China-based precision medicine researcher AnchorDX has secured in a $28m series B round backed by medical testing firm KingMed Diagnostics and pharmaceutical company WuXi AppTec, China Money Network reported yesterday.
Sijia Jianxin Fund co-led the round with 6 Dimensions Capital, a strategic investment vehicle formed by WuXi AppTec and venture capital firm Frontline BioVentures, while VC firm Arch Venture Partners and VC fund Marathon Venture Partners also took part.
Founded in 2015, AnchorDx is developing improved DNA and RNA sequencing…
